© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
January 21, 2013
Despite universal access to HER2 testing in Ontario, variability in reporting by region and disease severity presents challenges for program evaluation and quality improvement initiatives.
May 17, 2011
Economic evaluations of adjuvant trastuzumab were reviewed. Three primary shortcomings were identified including incorporation of local data and estimation and representation (visual) of decision uncertainty.
September 15, 2008
Osteoporosis treatment for high-risk women is cost-effective, with bisphosphonates providing the most benefit at the lowest cost.
April 01, 2006